Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

elotuzumab

- PMLiVE

Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate

The drug showed improvements in overall survival and progression-free survival in two cancers

- PMLiVE

J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

Roadmap visual

Where it all began – why we developed The Experience Gap

Learn how The Experience Gap was developed to help sponsors, CROs and site teams improve clinical trial participation by identifying friction points, enhancing patient experience, and driving better recruitment and...

Cuttsy + Cuttsy

The Experience Gap hero image

Cuttsy+Cuttsy launches a practical roadmap to enhance clinical trial participant experience

Cuttsy+Cuttsy has launched The Experience Gap, a practical roadmap designed to help clinical trial teams improve participant engagement, support and retention across the full study journey.

Cuttsy + Cuttsy

- PMLiVE

GSK signs agreement with Protas to streamline clinical trials

The new three-year agreement builds on an existing two-year relationship

- PMLiVE

Legend Biotech appoints new group of scientific advisors

The company is focused on CAR-T cell therapy to treat multiple myeloma

- PMLiVE

Biogen agrees $850m felzartamab rights deal with TJ Biopharma

The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases

- PMLiVE

myTomorrows partners with Rare Disease Research to boost rare disease referrals

The collaboration aims to improve patient identification and access to clinical trials

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

Site Factor report illustrations

Why patient-centricity depends on site-centricity in clinical trials

Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links